Efficacy of alemtuzumab in organ transplantation: Current clinical status

Gaetano Ciancio, George W Burke, Maria E. Warque, Joshua Miller

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

An overview of the past 5 years of clinical renal transplantation would include progress in (i) the development of protocols with new induction agents (non-depleting versus depleting monoclonal and polyclonal antibodies) designed to reduce the incidence and severity of acute rejection, (ii) the attempt to reduce calcineurin inhibitor short- and long-term nephrotoxicity, and (iii) the attempt to reduce immunosuppression overall if an immunoregulatory state ('tolerance') against donor alloantigens could be achieved. One such induction agent is the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath-1H), which depletes T cells (most potently), as well as B cells and other lymphoid subsets, and may decrease the dosage or need for concurrent maintenance immunosuppressive agents.

Original languageEnglish
Pages (from-to)85-92
Number of pages8
JournalBioDrugs
Volume20
Issue number2
StatePublished - May 9 2006

Fingerprint

Organ Transplantation
Isoantigens
Immunosuppressive Agents
Kidney Transplantation
Immunosuppression
B-Lymphocytes
Monoclonal Antibodies
Maintenance
T-Lymphocytes
Incidence
alemtuzumab
Calcineurin Inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Immunology and Allergy
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Efficacy of alemtuzumab in organ transplantation : Current clinical status. / Ciancio, Gaetano; Burke, George W; Warque, Maria E.; Miller, Joshua.

In: BioDrugs, Vol. 20, No. 2, 09.05.2006, p. 85-92.

Research output: Contribution to journalArticle

Ciancio, Gaetano ; Burke, George W ; Warque, Maria E. ; Miller, Joshua. / Efficacy of alemtuzumab in organ transplantation : Current clinical status. In: BioDrugs. 2006 ; Vol. 20, No. 2. pp. 85-92.
@article{02d43cabef8740da9795f5a34a61449c,
title = "Efficacy of alemtuzumab in organ transplantation: Current clinical status",
abstract = "An overview of the past 5 years of clinical renal transplantation would include progress in (i) the development of protocols with new induction agents (non-depleting versus depleting monoclonal and polyclonal antibodies) designed to reduce the incidence and severity of acute rejection, (ii) the attempt to reduce calcineurin inhibitor short- and long-term nephrotoxicity, and (iii) the attempt to reduce immunosuppression overall if an immunoregulatory state ('tolerance') against donor alloantigens could be achieved. One such induction agent is the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath-1H), which depletes T cells (most potently), as well as B cells and other lymphoid subsets, and may decrease the dosage or need for concurrent maintenance immunosuppressive agents.",
author = "Gaetano Ciancio and Burke, {George W} and Warque, {Maria E.} and Joshua Miller",
year = "2006",
month = "5",
day = "9",
language = "English",
volume = "20",
pages = "85--92",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Efficacy of alemtuzumab in organ transplantation

T2 - Current clinical status

AU - Ciancio, Gaetano

AU - Burke, George W

AU - Warque, Maria E.

AU - Miller, Joshua

PY - 2006/5/9

Y1 - 2006/5/9

N2 - An overview of the past 5 years of clinical renal transplantation would include progress in (i) the development of protocols with new induction agents (non-depleting versus depleting monoclonal and polyclonal antibodies) designed to reduce the incidence and severity of acute rejection, (ii) the attempt to reduce calcineurin inhibitor short- and long-term nephrotoxicity, and (iii) the attempt to reduce immunosuppression overall if an immunoregulatory state ('tolerance') against donor alloantigens could be achieved. One such induction agent is the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath-1H), which depletes T cells (most potently), as well as B cells and other lymphoid subsets, and may decrease the dosage or need for concurrent maintenance immunosuppressive agents.

AB - An overview of the past 5 years of clinical renal transplantation would include progress in (i) the development of protocols with new induction agents (non-depleting versus depleting monoclonal and polyclonal antibodies) designed to reduce the incidence and severity of acute rejection, (ii) the attempt to reduce calcineurin inhibitor short- and long-term nephrotoxicity, and (iii) the attempt to reduce immunosuppression overall if an immunoregulatory state ('tolerance') against donor alloantigens could be achieved. One such induction agent is the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath-1H), which depletes T cells (most potently), as well as B cells and other lymphoid subsets, and may decrease the dosage or need for concurrent maintenance immunosuppressive agents.

UR - http://www.scopus.com/inward/record.url?scp=33646240815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646240815&partnerID=8YFLogxK

M3 - Article

C2 - 16626166

AN - SCOPUS:33646240815

VL - 20

SP - 85

EP - 92

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 2

ER -